Corcept Therapeutics director sells 1,500 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Corcept Therapeutics Inc. director Daniel N. Swisher Jr. exercised options to acquire 1,100 common shares at $14.0800 per share and 400 shares at $10.5000 per share on November 10, 2026, and reported a sale of 1,500 common shares at $74.0700 per share that day. The sale was made pursuant to a Rule 10b5-1 plan adopted August 3, 2026; both options were fully exercisable. A footnote to the 400-share option says he previously transferred 12,500 shares underlying the option to his ex-spouse and no longer reports securities owned by her as beneficially owned.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F2 | 1,100 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F2, F3 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,100 | $14.08 | $15K |
| Exercise | Common Stock | 400 | $10.50 | $4K |
| Sale | Common Stock F1 | 1,500 | $74.07 | $111K |
Footnotes (3)
- F1. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 3, 2026 in effect at the time of this transaction.
- F2. Fully exercisable.
- F3. The Reporting Person previously transferred 12,500 shares underlying the stock option to his ex-spouse. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
Key Figures
Key Terms
10b5-1 plan regulatory
Fully exercisable financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What CORT stock options did Daniel N. Swisher Jr. exercise?
AI-generated analysis. How Rhea-AI works. Not financial advice.